Ionis Pharmaceuticals Stock (NASDAQ:IONS), Analyst Ratings, Price Targets, Predictions

The latest price target for Ionis Pharmaceuticals (NASDAQ: IONS) was reported by Wolfe Research on April 10, 2024. The analyst firm set a price target for $0.00 expecting IONS to fall to within 12 months (a possible -100.00% downside). 29 analyst firms have reported ratings in the last year.

The latest analyst rating for Ionis Pharmaceuticals (NASDAQ: IONS) was provided by Wolfe Research, and Ionis Pharmaceuticals upgraded their outperform rating.

The last upgrade for Ionis Pharmaceuticals Inc happened on April 10, 2024 when Wolfe Research raised their price target to N/A. Wolfe Research previously had a peer perform for Ionis Pharmaceuticals Inc.

The last downgrade for Ionis Pharmaceuticals Inc happened on December 21, 2022 when Morgan Stanley changed their price target from $56 to $40 for Ionis Pharmaceuticals Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Ionis Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Ionis Pharmaceuticals was filed on April 10, 2024 so you should expect the next rating to be made available sometime around April 10, 2025.

While ratings are subjective and will change, the latest Ionis Pharmaceuticals (IONS) rating was a upgraded with a price target of $0.00 to $0.00. The current price Ionis Pharmaceuticals (IONS) is trading at is $43.09, which is out of the analyst’s predicted range.